Atractylenolide III alleviates sepsis-mediated lung injury via inhibition of FoxO1 and VNN1 protein

Fu, Jiding; Gao, Chunhui; Li, Shiwei; Tian, Yan; Li, Shicheng; Yi-er, Wei; Xian, Lewu

doi:10.1590/acb360802

Cited by 8 publications

(5 citation statements)

References 36 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Increasing evidence suggests that miR-223 may limit in ammation to prevent collateral damage during infection, and FOXO1 is a validated target for miR-223 [21] . Ji-Ding Fu et al found that atractylenolide III alleviated sepsis-mediated lung injury by inhibiting FoxO1 and recombinant vanin 1 [22] .…”

Section: Discussionmentioning

confidence: 99%

Identifying Six Chromatin Remodeling-related Genes As Diagnostic Biomarkers in Sepsis Using Bioinformatic Analyses

Miao

et al. 2023

Preprint

View full text Add to dashboard Cite

Epigenetic modifications like chromatin remodeling play a vital role in regulating sepsis immunity. Understanding the role of chromatin remodeling in sepsis can help identify new potential therapeutic targets. Differentially expressed chromatin remodeling-related genes (DE-CRRGs) were identified between the sepsis and normal groups in GSE65682. LASSO regression, SVM, and random forest algorithms were employed to screen out six hub genes. The abundance of different immune cells in the two groups was determined using CIBERSORT. ceRNA regulatory and co-expression networks of the hub genes were constructed. Finally, using the Drug Gene Interaction Database to predict potential drugs for sepsis. Seventeen DE-CRRGs were identified, from which six hub genes were screened out: SPON2, TGM2, MMP9, DNMT1, LY96, and FOXO1. The infiltration of 16 types of immune cells differed significantly between the two groups. The hub genes were significantly correlated with activated NK cells, CD8 T cells, and plasma cells. Genes in the ceRNA regulatory and co-expression networks were mainly involved in interleukin-18 signaling, response to biological stimuli, positive regulation of cell development, etc. Finally, sixty-two drugs were predicted.

show abstract

Section: Discussionmentioning

confidence: 99%

Identifying Six Chromatin Remodeling-related Genes As Diagnostic Biomarkers in Sepsis Using Bioinformatic Analyses

Miao

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…The reason we did not find differences in T0, T1, and T3 groups may be the blood test interval is too short (within 3 h). Recently, some articles showed that inhibition of the VNN1 protein can alleviate the lung injury in sepsis and sepsis shock mice ( 22 , 23 ).…”

Section: Discussionmentioning

confidence: 99%

VNN1 as a potential biomarker for sepsis diagnosis and its implications in immune infiltration and tumor prognosis

Guan,

Xu,

Shi

et al. 2023

Front. Med.

View full text Add to dashboard Cite

BackgroundThis study explored novel biomarkers for diagnosing sepsis, a severe disease prevalent in clinical settings, particularly threatening to elderly patients.MethodsUsing microarray gene expression datasets and fatty acid metabolism signatures, we identified differentially expressed genes between sepsis and healthy control groups. Correlations between candidate genes, immune cells, and immune function were assessed. Logistic regression analysis and single-gene GSEA analysis were performed to identify potential biomarkers. The biomarkers’ association with different types of tumors was investigated.ResultsTwelve genes related to fatty acid metabolism were excluded. CA4, OLAN, and VNN1 were found relevant to immune cells and function. Among these, only VNN1 showed statistical significance (p < 0.05), with a strong area under the ROC curve (0.995). High VNN1 expression indicated activation of certain metabolic pathways, while low expression suggested potential autoimmune responses. VNN1 was up-regulated in eight tumors and down-regulated in eight others. High VNN1 expression was linked to poor prognosis in six types of tumors, and low expression was linked to poor prognosis in four types of tumors. VNN1 expression showed correlations with stromal scores, immune scores, and cancer purity in different types of tumors.ConclusionVNN1 holds promise as a potential biomarker for sepsis diagnosis and is significant in identifying immune infiltration in tumor tissue and predicting tumor prognosis.

show abstract

“…Zhang et al [ 92 ] discovered that ATL I protected mice against LPS-induced acute lung injury by suppressing TLR4 expression and NF-κB activation, as well as reducing inflammatory cytokine production. Another study determined that ATL III up-regulated the expression of FoxO1 and VNN1 proteins, inhibited the production of inflammatory molecules, and enhanced lung function and apoptosis in mice with sepsis-induced lung damage [ 93 ]. Huai et al [ 94 ] used bleomycin-induced pulmonary fibrosis model rats to discover that ATL III improved lung injury and function by promoting the Nrf2/NQO1/HO-1 pathway, decreasing Caspase-3, Caspase-9, TGF-β, and α-SMA expression, down-regulating IL-6, iNOS, and TNF-α levels, up-regulating IL-10 levels, and increasing SOD and GSH activity.…”

Section: Pharmacological Effects Of Atractylenolidesmentioning

confidence: 99%

Chemical Constitution, Pharmacological Effects and the Underlying Mechanism of Atractylenolides: A Review

Xie

Lin

et al. 2023

Molecules

View full text Add to dashboard Cite

Atractylenolides, comprising atractylenolide I, II, and III, represent the principal bioactive constituents of Atractylodes macrocephala, a traditional Chinese medicine. These compounds exhibit a diverse array of pharmacological properties, including anti-inflammatory, anti-cancer, and organ-protective effects, underscoring their potential for future research and development. Recent investigations have demonstrated that the anti-cancer activity of the three atractylenolides can be attributed to their influence on the JAK2/STAT3 signaling pathway. Additionally, the TLR4/NF-κB, PI3K/Akt, and MAPK signaling pathways primarily mediate the anti-inflammatory effects of these compounds. Atractylenolides can protect multiple organs by modulating oxidative stress, attenuating the inflammatory response, activating anti-apoptotic signaling pathways, and inhibiting cell apoptosis. These protective effects extend to the heart, liver, lung, kidney, stomach, intestine, and nervous system. Consequently, atractylenolides may emerge as clinically relevant multi-organ protective agents in the future. Notably, the pharmacological activities of the three atractylenolides differ. Atractylenolide I and III demonstrate potent anti-inflammatory and organ-protective properties, whereas the effects of atractylenolide II are infrequently reported. This review systematically examines the literature on atractylenolides published in recent years, with a primary emphasis on their pharmacological properties, in order to inform future development and application efforts.

show abstract

Atractylenolide III alleviates sepsis-mediated lung injury via inhibition of FoxO1 and VNN1 protein

Cited by 8 publications

References 36 publications

Identifying Six Chromatin Remodeling-related Genes As Diagnostic Biomarkers in Sepsis Using Bioinformatic Analyses

Identifying Six Chromatin Remodeling-related Genes As Diagnostic Biomarkers in Sepsis Using Bioinformatic Analyses

VNN1 as a potential biomarker for sepsis diagnosis and its implications in immune infiltration and tumor prognosis

Chemical Constitution, Pharmacological Effects and the Underlying Mechanism of Atractylenolides: A Review

Contact Info

Product

Resources

About